Compounds for treating CMV related diseases
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite D'Aix-Marseille
InventorsPierre Szepetowski, Robin Cloarec, Sylvian Bauer, Nadine Bruneau
Life of this patent
Estimating the term…
Abstract
The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.
Claims12
A method of treating cytomegalovirus (CMV) related diseases in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound that modifies microglia,
- wherein the compound is clodronate or a tetracycline family compound, and
- wherein the CMV related disease is a disorder associated with perinatal or congenital CMV infection selected from the group consisting of microcephaly, polymicrogyria, hearing loss, cerebral palsy, epileptic seizures and intellectual disability.
A method of treating or inhibiting at least one cytomegalovirus (CMV) related neurodevelopmental disorder in a foetus in need thereof, comprising administering to a pregnant female or the foetus in utero a therapeutically effective amount of a compound which reduces activity of microglia or depletes the microglia, wherein said compound is clodronate or a tetracycline family compound.
A method of treating or inhibiting at least one cytomegalovirus (CMV) related neurodevelopmental disorder in a newborn baby in need thereof, comprising administering to the newborn baby a therapeutically effective amount of a compound which reduces activity of microglia or depletes the microglia, wherein said compound is clodronate or a tetracycline family compound.
Dependencies are inferred from the claim text.